drugset / Trial / NCT04815967
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2/3
Terminated
32 enrolled
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of upper limb spasticity in adults followed by an open-label extension safety trial.
Timeline
- Start
- 2021-11-02
- Primary completion
- 2023-04-23
- Completion
- 2023-04-23
Outcome
Outcome not reported
Stopped (Business): “Company/sponsor business decision; not due to or related to any safety concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum Toxin Type B | Unknown | 10000 iu | Intramuscular |
| Subject | Botulinum Toxin Type B | Unknown | 15000 iu | Intramuscular |
| Subject | Botulinum Toxin Type B | Unknown | 20000 iu | Intramuscular |